Dubey Nandini, Bellamy Fiona, Bhat Sameer, MacFacter Wiremu, Rossaak Jeremy
Department of General Surgery, Tauranga Hospital, Te Whatu Ora, Tauranga, Aotearoa, New Zealand.
Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, Aotearoa, New Zealand.
Br J Anaesth. 2024 Mar;132(3):562-574. doi: 10.1016/j.bja.2023.11.046. Epub 2023 Dec 21.
Pain is common after laparoscopic abdominal surgery. Intraperitoneal local anaesthetic (IPLA) is effective in reducing pain and opioid use after laparoscopic surgery, although the optimum type, timing, and method of administration remains uncertain. We aimed to determine the optimal approach for delivering IPLA which minimises opioid consumption and pain after laparoscopic abdominal surgery.
MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL) databases were systematically searched for randomised controlled trials comparing different combinations of the type (bupivacaine vs lidocaine vs levobupivacaine vs ropivacaine), timing (pre-vs post-pneumoperitoneum at the beginning or end of surgery), and method (aerosol vs liquid) of IPLA instillation in patients undergoing any laparoscopic abdominal surgery. A network meta-analysis was conducted to ascertain the optimum approach for delivering IPLA resulting in the least cumulative opioid consumption and pain (overall and localising to the shoulder) 24 h after surgery. Certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) assessments (PROSPERO ID: CRD42022307595).
Twenty-five RCTs were included, among which 15 different combinations of delivering IPLA were analysed across 2401 participants. Aerosolised bupivacaine instilled at the end of surgery, before deflation of the pneumoperitoneum, was associated with significantly less postoperative opioid consumption compared with all other approaches for delivering IPLA (98.7% of comparisons; moderate certainty), aside from liquid levobupivacaine instilled before surgery and during or after creation of the pneumoperitoneum (mean difference -11.6, 95% credible interval: -26.1 to 2.5 i.v. morphine equivalent doses). There were no significant differences between different IPLA approaches regarding overall pain scores and incidence of shoulder pain up to 24 h after surgery.
There are limited studies and low-quality evidence to conclude on the optimum method of delivering IPLA in laparoscopic abdominal surgery. While aerosolised bupivacaine instilled at the end of surgery but before deflation of the pneumoperitoneum minimises postoperative opioid consumption, pain scores up to 24 h did not differ between the different modalities of delivering IPLA. The generalisability of these results is limited by the lack of utilisation of non-opioid analgesics in most trials.
PROSPERO CRD42022307595.
腹腔镜腹部手术后疼痛很常见。腹膜内局部麻醉(IPLA)在减少腹腔镜手术后疼痛和阿片类药物使用方面有效,尽管最佳类型、时机和给药方法仍不确定。我们旨在确定提供IPLA的最佳方法,以尽量减少腹腔镜腹部手术后的阿片类药物消耗和疼痛。
系统检索MEDLINE、Embase、Scopus和Cochrane对照试验中央注册库(CENTRAL)数据库,以查找比较接受任何腹腔镜腹部手术患者IPLA滴注的类型(布比卡因与利多卡因与左旋布比卡因与罗哌卡因)、时机(手术开始或结束时气腹前与气腹后)和方法(气雾剂与液体)的不同组合的随机对照试验。进行网络荟萃分析,以确定提供IPLA的最佳方法,该方法可使术后24小时的累积阿片类药物消耗和疼痛(总体和肩部局部疼痛)最少。使用推荐分级、评估、制定和评价(GRADE)评估(PROSPERO编号:CRD42022307595)评估证据的确定性。
纳入了25项随机对照试验,其中对2401名参与者分析了15种不同的IPLA给药组合。与所有其他IPLA给药方法相比,在手术结束时、气腹放气前滴注雾化布比卡因与术后阿片类药物消耗显著减少相关(98.7%的比较;中等确定性),除了在手术前以及气腹建立期间或之后滴注液体左旋布比卡因(平均差异-11.6,95%可信区间:-26.1至2.5静脉注射吗啡当量剂量)。在术后24小时内,不同IPLA方法在总体疼痛评分和肩部疼痛发生率方面没有显著差异。
关于腹腔镜腹部手术中IPLA给药的最佳方法,研究有限且证据质量低。虽然在手术结束时但在气腹放气前滴注雾化布比卡因可使术后阿片类药物消耗最少,但在24小时内不同IPLA给药方式的疼痛评分没有差异。这些结果的普遍性受到大多数试验中未使用非阿片类镇痛药的限制。
PROSPERO CRD42022307595。